A phase 1b/2, open-label study of amivantamab monotherapy or in combination with standard-of-care chemotherapy in participants with advanced or metastatic colorectal cancer. This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results